May 20th 2024
A study found that a novel ointment improved symptoms in patients with cutaneous T-cell lymphoma. The treatment was well-tolerated with minimal adverse effects.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
T-Cell Attributes of Axi-cel Correlate With Outcomes in Large B-Cell Lymphoma
April 11th 2022CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.
Read More
FDA Discourages Marketing Authorization for Zandelisib in Patients With FL or MZL
March 25th 2022The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.
Read More
Bortezomib Shows Survival Benefit in Children With T-Cell Lymphoblastic Lymphoma
March 14th 2022The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.
Read More
Tisagenlecleucel Not Superior to SOC as 2L Treatment for Aggressive B-cell Lymphoma
March 10th 2022Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.
Read More
FDA Grants Priority Review to Liso-Cel for Adults With Relapsed/Refractory LBCL
February 17th 2022The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.
Read More
Use of Axi-Cel in Previously Excluded LBCL Populations Supported by Real-World Evidence
December 13th 2021While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.
Read More